Arbutus Q2 FY26 net loss widens to $5.1 million; revenue drops 90.56% to $1.01 million

Reuters2026/08/12 11:37

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Arbutus Biopharma posted a Q2 net loss of $5.1 million, swinging from net income of $2.5 million a year earlier.
Revenue slid 90.56% to $1 million, due to recognition of $9.6 million deferred revenue in Q2 2025 after the Qilu partnership ended.
R&D expense fell 47.27% to $2.9 million, on workforce reductions, ending in-house research, and lower clinical trial costs.
Cash, cash equivalents and marketable securities totaled $92.6 million at June 30, 2026; received $178.4 million in July from the Moderna settlement.
Plans to repurchase up to about $230 million of shares starting Q3; filed international patent enforcement suits against Pfizer and BioNTech.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arbutus Biopharma Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608120730PRIMZONEFULLFEED9808344) on August 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Arbutus Q2 FY26 net loss widens to $5.1 million; revenue drops 90.56% to $1.01 million

You may also like

Crypto prices